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ABSTRACT
Objective Etrolizumab (rhuMAb β7, anti-β7,
PRO145223) is a humanised monoclonal antibody
targeting the β7 subunit of the heterodimeric integrins
α4β7 and αEβ7, which are implicated in leucocyte
migration and retention in ulcerative colitis (UC). This
randomised phase I study evaluated the safety and
pharmacology of etrolizumab in patients with moderate
to severe UC.
Design In the single ascending dose (SAD) stage,
etrolizumab (0.3, 1.0, 3.0, 10 mg/kg intravenous,
3.0 mg/kg subcutaneous (SC) or placebo) was
administered 4:1 (n=25) in each cohort. In the multiple
dose (MD) stage, new patients received monthly
etrolizumab (0.5 mg/kg SC (n=4), 1.5 mg/kg SC (n=5),
3.0 mg/kg SC (n=4), 4.0 mg/kg intravenous (n=5)) or
placebo (n=5). The pharmacokinetics was studied and
Mayo Clinic Score evaluated at baseline, day 29 (SAD),
and days 43 and 71 (MD).
Results In the SAD stage, there were no dose limiting
toxicities, infusion or injection site reactions. Two
impaired wound healing serious adverse events occurred
in two patients receiving etrolizumab. In the MD stage,
there were no dose limiting toxicities, and no infusion or
injection site reactions. Headache was the most common
adverse event, occurring more often in etrolizumab
patients. Antietrolizumab antibodies were detected in
two subjects. The duration of β7 receptor full occupancy
was dose related. A clinical response was observed in
12/18 patients, and clinical remission in 3/18 patients
treated with etrolizumab in the MD stage, compared
with 4/5 and 1/5 placebo patients, respectively.
Conclusion Etrolizumab is well tolerated in moderate
to severe UC. Further investigation is warranted.
INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory
condition of the colon characterised by mucosal
ulceration, rectal bleeding, diarrhoea, abdominal
pain and sometimes extraintestinal manifestations.1
UC may be complicated by severe bloody diarrhoea
and toxic megacolon that requires colectomy.2
Pharmacological management of UC currently
relies on 5-aminosalicylates, corticosteroids, purine
antimetabolites, calcineurin inhibitors such as tacro-
limus and cyclosporine, and antitumour necrosis
factor (anti-TNF) therapy. Corticosteroid depend-
ence and probability of colectomy remain clinically
significant challenges, the latter most commonly
due to failed medical therapy.
Sustained remission in inflammatory bowel
disease (IBD) with currently available therapies is
achieved in no more than 20%–30% of patients
with chronic disease.3 4 Patients treated with
anti-TNF therapy eventually lose response and are
at risk of serious side effects.5 6 Therefore, there is
a need to develop more targeted therapies opti-
mised for chronic use that can modify the disease
while decreasing dependence on corticosteroids
and the probability of progression to surgery,
without compromising immune competence. New
therapies should provide improved safety profiles
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Significance of this study
What is already known on this subject?
▸ Migration of lymphocytes to the gut is a key
feature of inflammation in inflammatory bowel
disease.
▸ Selective antimigration therapies are currently
developed and specific inhibition of homing of
lymphocytes to the gut is currently aimed at for
therapy.
▸ These new therapies target the α4β7–
MadCam-1 interaction.
What are the new findings?
▸ Etrolizumab (antibodies to β7) does inhibit the
migration of lymphocytes to the gut and
antagonises the retention of lymphocytes in the
mucosa by blocking the αEβ7–E-cadherin
interaction.
▸ This phase I study in severe ulcerative colitis
shows suitable pharmacokinetics and the early
safety of this treatment.
▸ Clinical improvement of the disease observed in
treated patients warrants further phase II
studies.
How might it impact on clinical practice in
the foreseeable future?
▸ We hypothesise that a therapy that blocks
migration of lymphocytes to the gut and
recruiting of effector lymphocytes from the gut
would be more effective than therapies
blocking migration alone.
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with sustained remission and mucosal healing, thereby prevent-
ing long-term complications in a greater proportion of patients,
including patients who do not respond to standard of care.
Integrins are cell surface glycoproteins that play a role in
leucocyte adhesion, signalling, proliferation and migration,7
aiding in leucocyte recruitment from blood into both lymphoid
and non-lymphoid tissues in a highly regulated manner.8
Migration into the gastrointestinal tract is highly dependent on
interactions between the α4β7 integrin expressed on the surface
of the leucocyte and its ligand, mucosal addressin cell adhesion
molecule (MAdCAM-1) expressed on endothelial cells.9 α4β7
Binds preferentially to MAdCAM-1 expressed on the high endo-
thelial venules of mucosal-associated lymphoid tissues, and has
limited binding to vascular cell adhesion molecule 1 (VCAM-1)
and the fibronectin fragment CS-1.10–12 α4β7+ Cells and
MAdCAM-1 expression are elevated at sites of chronic inflam-
mation such as in the intestinal tract of patients with UC.13 14
The αEβ7 integrin, another member of the β7 integrin family,
is expressed exclusively on mucosal intraepithelial T lympho-
cytes. αEβ7 binds selectively to E-cadherin on epithelial cells
and has been proposed to play a role in the retention of T cells
in mucosal tissue,15–17 which exhibit cytotoxicity against
stressed or infected epithelial cells.18–20 The expression of αEβ7
is elevated in UC and Crohn’s Disease (CD) in the active phase
of the disease,21 22 and anti-αEβ7 treatment attenuates experi-
mental colitis in mice, implicating a role for αEβ7+ lympho-
cytes in experimental models of IBD.23 Interestingly, genetic
polymorphisms at the CDH1 locus, which encode E-cadherin,
have been associated with susceptibility to UC.24 25 In addition,
CDH1 polymorphisms associated with CD may result in the
generation of a truncated E-cadherin protein with abnormal
intracellular accumulation and impaired plasma membrane local-
isation.26 Studies of gene targeted animals with E-cadherin
defects in the gut epithelium have demonstrated that this
protein is critical for maintenance of intestinal epithelial integ-
rity and defense.27 28 Thus, while alterations in the E-cadherin
homotypic interactions likely underlie the increased disease sus-
ceptibility associated with CDH1 polymorphisms, dysregulated
E-cadherin expression or function may also result in altered
αEβ7+ cell responses.
Etrolizumab is a humanised IgG1 monoclonal antibody which
targets the β7 subunit of the α4β729 30 and αEβ715 integrins
with high affinity, blocking binding to their ligands,
MAdCAM-1 and E-cadherin, respectively. Murine and primate
studies indicate that etrolizumab provides selective targeting of
lymphocyte homing to mucosal sites, with limited to no effects
on migration to non-mucosal tissues.31 32 Amelioration of IBD
in nonclinical models is associated with downmodulation and/or
disappearance of α4β7 and αEβ7 cells from the inflamed
mucosa.33–38
Etrolizumab provides a dual approach mechanism of action
for the treatment of IBD that involves inhibition of leucocyte
trafficking to the gut (through blocking of α4β7–MAdCAM-1
interactions) as well as inhibition of retention of leucocytes in
the intraepithelial lining of the gut (through blocking αEβ7–
E-cadherin interactions), which may provide improved efficacy
over currently available therapies.
MATERIALS AND METHODS
A randomised, placebo-controlled, double-blind within-cohort
study was designed to evaluate the safety and tolerability of
etrolizumab in patients with moderate to severe UC. Secondary
objectives included the characterisation of the pharmacokinetic
(PK) profile, and to conduct an initial assessment of
immunogenicity. Exploratory objectives were to evaluate phar-
macodynamic (PD) properties and evaluate potential clinical
activity. Study participants were recruited from 15 centres in
Canada, the USA and Europe (the UK, Belgium, The
Netherlands, Germany). Institutional review boards at each
study site approved the protocol, and all subjects provided
written informed consent. The trial was registered under US
National Institutes of Health ClinicalTrials.gov identifier
NCT00694980.
Patients
Eligible patients included male and female subjects, 18–70 years
of age, with a diagnosis of UC and a Mayo Clinic Score
(MCS)39 of ≥5 points at screening. Patients had a disease dur-
ation of ≥12 weeks at screening, and were on stable doses of
oral 5-aminosalicylic acid (2.4–4.8 g/day) or oral steroids
(≤20 mg/day of prednisone or prednisone equivalent), or
azathioprine, 6-mercaptopurine or methotrexate. Key exclusion
criteria included hospitalisation due to severity of UC; evidence
of moderate to severe anaemia (haemoglobin <10 g/dl); risk of
infection including presence of JCV DNA in serum, such as
ongoing or history of severe infections; recent live vaccinations;
concomitant medications including anti-TNF, cyclosporine or
tacrolimus within 3 months; and any manifestation of UC or
other conditions likely to require, in the investigator’s judge-
ment, treatment with >20 mg/day of prednisone or prednisone
equivalent.
Study design
We initiated a randomised within cohort single ascending dose
(SAD) stage followed by a randomised within cohort, multiple
dose (MD), parallel-treatment stage. The interactive voice
response system conducted the randomisation/treatment assign-
ment through the use of a process designed by the biostatisti-
cian. In the SAD stage of the study, patients (n=5/cohort; 4
etrolizumab to 1 placebo; total n=25) were enrolled sequen-
tially, in ascending doses, into five cohorts (Cohorts A–E) and
treated with single intravenous or subcutaneous (SC) doses at
one of four dose levels (0.3, 1.0, 3.0 or 10.0 mg/kg) (figure 1).
Enrolment in one cohort was completed before the next cohort
opened. In the first dose cohort (Cohort A, 0.3 mg/kg intraven-
ous) no more than one patient was treated per 24 h, and each
patient was monitored for 24 h for acute adverse reactions
before the next patient was treated. Within subsequent cohorts
(Cohorts B–E), dosing of the first two patients in each cohort
was staggered by 24 h.
Figure 1 Study design and patient flow. IV, intravenous; SC,
subcutaneous; SAO, single ascending dose; DE, dose escalation.
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Safety was evaluated after a cohort had completed enrolment
and all patients in the cohort had completed follow-up through
day 15. If the safety data were acceptable as determined by the
number of dose limiting toxicities (DLTs), then enrolment of the
subsequent cohort was initiated. Patients were followed for
18 weeks after the single dose of study drug was administered,
with follow-up visits at days 1, 2, 4, 8, 15, 22, 29, 43, 57, 71,
99 and 127.
The MD parallel stage was commenced ∼10 weeks after
dosing was completed for the last patient treated in Cohort E
(3.0 mg/kg SC) of the SAD stage, and was conditional on
adequate PK properties being observed in the SAD stage and
establishment of a maximum tolerated dose (MTD) for etrolizu-
mab of >10 mg/kg intravenous. In the MD stage, patients were
enrolled concurrently and randomised within cohort to receive
placebo (n=5) or etrolizumab at the following doses: 0.5 mg/kg
SC (Cohort F; n=4), 1.5 mg/kg SC (Cohort G; n=5), 3.0 mg/kg
SC (Cohort H; n=4) or 4.0 mg/kg intravenous (Cohort I; n=5).
In the MD stage, no patients were enrolled who participated in
the SAD stage.
Patients were treated with single intravenous or SC doses
every 4 weeks for three cycles, at days 1, 29 and 57. Patients
were followed for safety for 20 weeks (through day 197) after
the final dose of study drug was administered during the MD
stage of the study.
Assessments
Safety
Safety data were assessed at each visit and graded according to
the National Cancer Institute Common Toxicity Criteria
Adverse Event (NCI CTCAE), V.3.0. A DLTwas defined as any
NCI CTCAE Grade ≥3 adverse event (AE) occurring within
14 days of study drug administration during the SAD stage of
the study. Grade 3 infusion related toxicities were considered
DLTs. Exacerbation of UC was not considered a DLT. The MTD
was defined as the dose level below the one at which ≥2 patients
treated with etrolizumab experienced a DLT. It was determined
in the protocol that if no more than one patient experienced a
DLT in each of the five SAD cohorts, the MTD will not have
been defined and the highest tested dose will be 10 mg/kg
intravenous.
All patients were required to have undetectable JCV DNA in
the serum in order to take part in the study. Each patient under-
went regular cognitive assessment and completed a progressive
multifocal leucoencephalopathy (PML) symptom assessment
interview during the treatment and safety follow-up stages of
the study. Any patient who developed detectable JCV DNA in
the serum during the study had neurological assessment by a
neurologist and a brain MRI. There was also a PML expert
panel available to evaluate and adjudicate in real time any sus-
pected cases of PML. After completion of the safety follow-up
stage of the study, as per the study risk-monitoring plan, patients
were monitored for signs and symptoms of PML for a total of
2 years following initial dosing with the study drug using the
PML Symptom Assessment Interview. Total and differential
white cell count was also measured during the 2-year follow-up.
Pharmacokinetics
In the SAD stage of the study, PK serum samples were obtained
predose, postdose on study day 1 (1 h-intravenous only and 4 h)
and then on study days 2, 4, 8, 15, 22, 29, 43, 57, 71, 99 and
127 (or at early treatment termination). In the MD stage, PK
serum samples were obtained on days 1 (predose, 1 h
postdose-intravenous only, 4 h postdose), days 2, 15 and 29
(predose, 1 h postdose-intravenous only, 4 h postdose), days 30,
43 and 57 (predose, 1 h postdose-intravenous only, 4 h post-
dose) and days 58, 60, 64, 67, 71, 85, 99, 113, 141, 169 and
197 (or at early treatment termination).
Etrolizumab concentration was determined using a validated
ELISA assay with a lower limit of quantification of 0.0125 μg/
ml. The following PK parameters were assessed: maximum
serum concentration (Cmax), area under concentration–time
curve from time 0 to infinity, SAD (AUC), area under concentra-
tion–time curve during a dosing interval, MD (AUCτ), total
body clearance at steady state after intravenous doses (CLss) or
apparent total body clearance at steady state after SC doses
(CLss/F) and elimination half-life (t1/2z). PK parameters were cal-
culated using a standard non-compartmental method with the
computer program WinNonlin V.5.2.1 (Pharsight Corporation,
Mountain View, California, USA).
For antitherapeutic antibody (ATA) measurement, serum
samples were collected at study days 1 (predose) and days 15,
29, 57, 99 and 127 in the SAD stage. For the MD stage,
samples were collected at days 1 (predose), day 29 (predose),
day 57 (predose) and days 64, 85, 113, 141, 169 and 197.
Serum was analysed for the development of ATAs using a vali-
dated antibody-bridging electrochemiluminesence assay. Serum
samples were first screened for the presence of ATAs. Samples
that screened positive for ATAwere confirmed by immunodeple-
tion. Samples with confirmed ATA responses were further
diluted to obtain titre values. ATAs in serum were detected with
a minimum reportable titre of 1.30 titre units (corresponding to
a minimum 1/20 sample dilution).
PD evaluations
Drug occupancy on target CD4+ lymphocytes (‘available’ β7
receptors) following single or multiple intravenous or SC
administration of etrolizumab was evaluated on subsets of CD4
+ T cells in peripheral blood of patients. CD4+ T cells were
assessed by flow cytometry according to expression of CD45RA
and β7, and phenotypically subdivided according to homing
properties into subsets of CD4+CD45RA-β7high T cells
(mucosal-homing), CD4+CD45RA-β7low T cells (peripheral
homing) and CD4+ CD45RA+ T cells (cells that traffic well to
both intestinal and peripheral lymph nodes and tissues).40
In the SAD stage of the study, peripheral blood samples were
obtained at screen, day 1 (predose) and days 2, 8, 15, 22, 29,
43, 57, 71, 99 and 127. In the MD stage, peripheral blood
samples were obtained at screen, day 1 (predose), days 2, 15
and 29 (predose), days 30, 43 and 57 (predose) and days 58,
64, 72, 85, 99, 113, 141, 169 and 197.
Occupancy of etrolizumab was assessed using fluorescently-
labelled etrolizumab. The absolute number (ABS) of T lympho-
cyte subsets was assessed at each time point and expressed as a
percentage of predose baseline (% BL) T lymphocytes. Baseline
was defined as the average of the predose (screen and day 1
predose) values. For each cohort, the mean absolute count (%
BL) for patients treated with etrolizumab was calculated. Placebo
patients from the single and MD cohorts were combined and
used as the controls for the single and MD analyses, respectively.
Correlative analysis of pharmacokinetics and pharmacodynamics
A total of 38 etrolizumab treated patients were evaluated to
determine the minimal serum etrolizumab concentration that is
required to maintain full occupancy of the β7 integrin. Five of
the 38 treated patients were excluded from the PK/PD analysis
due to missing PK and PD values as they terminated early from
the study.
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Clinical activity
Exploratory analyses were conducted for the SAD and MD
stages to evaluate the effect of etrolizumab on the MCS com-
pared with baseline on days 29 (SAD only) and days 43 and 71
(MD stage only). A clinical response was defined as ≥3 points
and 30% reduction from baseline in MCS, and ≥1 point
decrease in rectal bleeding subscore or absolute rectal bleeding
score of 0 or 1. Clinical remission was defined as MCS ≤2 with
no individual subscore exceeding 1 point.
Statistical analysis
The cohort sample size was determined by estimating the
minimum number or patients required to safely escalate at dif-
ferent DLT rates to the next dose level in the SAD. All patients
who received at least one dose of study drug or placebo were
included in the safety, PK and PD analyses. AEs, vital signs,
laboratory tests, PK, PD and disease activity measurements were
descriptively compared across the various treatment groups with
no formal statistical testing.
RESULTS
Study population
Patient characteristics were similar between active drug and
placebo recipients (table 1) in both the SAD and MD stages of
the study. Information on previous therapy with anti-TNF was
not available for patients who took part in the SAD stage of the
study. In the MD stage, concomitant treatment for UC was
imbalanced between placebo and the active treatment arms with
a greater proportion of placebo patients receiving concomitant
corticosteroid therapy (80% placebo vs 44% for etrolizumab).
In addition, among patients who received active treatment with
etrolizumab, there were a greater proportion of patients who
had been treated with anti-TNF therapy (76% etrolizumab vs
40% on placebo). The mean MCS for patients participating in
the phase I study was 9.0±1.7 (SD) indicating they had severe
UC.
The demographics and baseline characteristics for patients
enrolled in the SAD and MD stages, per cohort, are presented
in Supplementary table 1. Although each cohort has data for
only four or five patients, these covariates appear balanced
across cohorts. The only covariate with a high variability is
disease duration, higher in the 1 mg/kg intravenous and 3 mg/kg
intravenous than the other SAD cohorts.
Patient disposition
Overall, 26 patients in the etrolizumab group and seven patients
in the placebo group completed the study. Of the 25 subjects
enrolled in the SAD stage, seven subjects discontinued early
from the study, five in the etrolizumab treated groups and two
in the placebo group. Of the 23 subjects enrolled in the MD
stage, eight subjects discontinued early from the study: seven in
the etrolizumab treated groups and one in the placebo group.
Subject disposition and the reasons for premature discontinu-
ation for subjects treated during the SAD and MD stages of the
study are presented in table 2.
Safety
Etrolizumab was well tolerated during the study. The overall
incidence of treatment-related AEs was marginally higher in the
active treatment group (table 3), and occurred in the first 24 h
of treatment. There was no dose-dependent increase in the inci-
dence of AEs. Headache was the most common AE occurring
more often in actively treated patients. No DLTs or clinically sig-
nificant infusion reactions or injection site reactions were
reported.
Eight patients had serious AEs: seven in the SAD stage (6:1;
etrolizumab:placebo) and one in the MD stage (1:0; etrolizu-
mab:placebo). Exacerbation of UC was the most common
serious AE. There were two patients with impaired wound
healing posturgent colectomy for exacerbation of UC. Both
patients had severe UC with baseline MCS of 9 and 11. Each
patient received a single dose of etrolizumab at dose levels of
1 mg/kg intravenous and 3 mg/kg SC, respectively. There were
significant confounding factors for impaired wound healing
such as the use of high dose steroids, hypoalbuminemia, type 2
diabetes mellitus and obesity in one patient, and hypoalumine-
mia and obesity in the second patient. Two other patients also
underwent colectomy after exposure to single doses of etrolizu-
mab in the phase I study without any postoperative
complications.
Two patients, one in the SAD stage and one in the MD stage,
developed transient low level JCV shedding into the serum at
levels of 20–30 viral copies/ml. Neither patient developed any
symptoms suggestive of PML and both had no significant abnor-
malities on brain MRI.
Pharmacokinetics
The PK behaviour of etrolizumab was generally consistent with
that of a typical humanised IgG1 monoclonal antibody (figure 2).
The PK profile of etrolizumab is generally linear and dose
Table 1 Patient demographics and baseline characteristics
Etrolizumab SAD (n=20) Placebo SAD (n=5) Etrolizumab MD (n=18) Placebo MD (n=5)
Gender, male (%) 15 (75) 2 (40) 13 (72) 3 (60)
Age (years), mean (SD) 40.3 (10.5) 30.2 (11) 44 (14) 39 (19)
Disease duration years, median (range) 8 (2–24) 6 (5–29) 6.5 (2–30) 5.3 (2–25)
Concomitant drug treatment, n (%)
5-ASA 12 (60) 4 (80) 12 (67) 2 (40)
Azathioprine 3 (15) 1 (20) 2 (11) 1 (20)
Mercaptopurine 2 (10) 0 (0) 0 (0) 0 (0)
Methotrexate 1 (5) 0 (0) 1 (6) 0 (0)
Corticosteroids 11 (55) 3 (60) 8 (44) 4 (80)
Previous anti-TNF therapy, n (%) NA NA 13 (72) 2 (40)
Baseline MCS, median (range) 9 (5–12) 9 (7–10) 10 (4–12) 10 (8–11)
5-ASA, 5-aminosalicylic acid; MCS, Mayo Clinic Score; MD, multiple dose; NA, not applicable; SAD, single ascending dose; TNF, tumour necrosis factor.
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proportional with regard to Cmax and AUC (SAD) or AUCτ (MD)
within the dose range tested. A slight trend of nonlinearity was
observed at doses ≤1.0 mg/kg, possibly due to target-mediated
clearance at lower etrolizumab serum concentrations. The slight
non-linearity of PK at doses ≤1.0 mg/kg resulted in a shorter
mean t1/2z at lower doses (4.8–7.4 days at 0.3–1 mg/kg) com-
pared with higher doses (10.6–13.1 days at 3–10 mg/kg). These
slight differences in half-life and PK linearity had no impact on
the exposures (Cmax, AUC) and the overall PK dose proportional-
ity across the dose ranges tested. The apparent bioavailability fol-
lowing a single SC administration, based on cross-cohort
comparison with intravenous single dose, was estimated to be
approximately 67% at 3 mg/kg. Mean CLss/F ranged from 5.1 to
10.1 ml/day/kg following multiple SC doses and showed no time-
dependent changes as compared with a single SC administration.
The repeated monthly dosing for three doses resulted in moder-
ate drug accumulation over time (accumulation ratio for AUCτ of
approximately 1.2-fold for intravenous and 2.0-fold for SC).
Antietrolizumab antibodies were detected in two out of a
total of 38 drug-treated patients. One patient was from the
lowest dose cohort in the SAD stage (0.3 mg/kg intravenous)
with positive ATA detected in a range of 1.6–2.02 titre units on
study day 29 and all subsequent ATA sample collection days up
to day 197. Another patient was from the lowest dose cohort in
the MD stage of the study (0.5 mg/kg SC) with positive ATA
confirmed by immunodepletion but with < 1.3 titre units on
study day 169 and 1.44 titre units on study day 197. In these
two ATA positive patients, the ATA titre levels were low and
close to the minimum reportable level (1.3 titre unit). There
were no effects on PK profile for either of these patients nor
were there any AEs suggestive of an allergic reaction.
Pharmacodynamics
Etrolizumab occupied β7 integrin on CD45RA-β7high CD4+ T
cells in all cohorts (ABS, % BL, figure 3). There was an observed
Table 2 Study completion status
SAD stage
No. (%) of patients
Placebo
(n=5)
0.3 mg/kg IV
(n=4)
1.0 mg/kg IV
(n=4)
3.0 mg/kg IV
(n=4)
3.0 mg/kg SC
(n=4)
10.0 mg/kg IV
(n=4)
All active
(n=20)
Study completion status
Subjects completed study 3 (60) 3 (75) 4 (100) 2 (50) 3 (75) 3 (75) 15 (75)
Subjects discontinued early 2 (40) 1 (25) 0 (0) 2 (50) 1 (25) 1 (25) 5 (25)
Reasons for study termination
Physician decision to withdraw subjects
from study
2 (40) 1 (25) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5)
Subjects’ decision to withdraw 0 (0) 0 (0) 0 (0) 0 (0) 1 (25) 1 (20) 2 (10)
Adverse event 0 (0) 0 (0) 0 (0) 2 (50) 0 (0) 0 (0) 2 (10)
MD stage
No. (%) of patients
Placebo
(n=5)
0.5 mg/kg SC
(n=4)
1.5 mg/kg SC
(n=5)
3.0 mg/kg SC
(n=4)
4.0 mg/kg IV
(n=5)
All Active
(n=18)
Study completion status
Subjects completed study 4 (80) 3 (75) 2 (40) 2 (50) 4 (80) 11 (61)
Subjects discontinued early 1 (20) 1 (25) 3 (60) 2 (50) 1 (20) 7 (39)
Reasons for study termination
Physician decision to withdraw subjects from study 0 (0) 0 (0) 1 (20) 1 (25) 0 (0) 2 (11)
Subjects’ decision to withdraw 1 (20) 0 (0) 1 (20) 1 (25) 0 (0) 2 (11)
Adverse event 0 (0) 1 (25) 1 (20) 0 (0) 1 (20) 3 (17)
IV, intravenous; MD, multiple dose; SAD, single ascending dose; SC, subcutaneous.
Table 3 Safety outcomes
No. (%) of patients
Etrolizumab (SAD +
MD) (n=38) Placebo (n=10)
All-cause
Treatment-
related All-cause
Treatment-
related
Adverse events
Any event 36 (95) 19 (50) 10 (100) 6 (60)
Exacerbation of UC 16 (42) 1 (3) 8 (80) 0 (0)
Headache 12 (32) 4 (11) 2 (20) 0 (0)
Fatigue 6 (16) 2 (5) 0 (0) 0 (0)
Abdominal pain 6 (16) 0 (0) 1 (10) 0 (0)
Dizziness 5 (13) 2 (5) 1 (10) 0 (0)
Nasopharyngitis 6 (16) 1 (3) 2 (20) 1 (10)
Nausea 5 (13) 4 (11) 1 (10) 0 (0)
Arthralgia 4 (11) 1 (3) 0 (0) 0 (0)
Urinary tract infection 4 (11) 2 (5) 0 (0) 0 (0)
Back pain 2 (5) 2 (5) 2 (20) 1 (10)
Vision blurred 2 (5) 1 (3) 0 (0) 0 (0)
Upper respiratory tract
infection
2 (5) 1 (3) 2 (20) 0 (0)
Conjunctivitis 1 (3) 1 (3) 0 (0) 0 (0)
Gastroenteritis 1 (3) 0 (0) 1 (10) 1 (10)
Serious adverse events
Any event 7 (18) 2 (5) 1 (10) 0 (0)
Exacerbation of UC 4 (11) 0 (0) 1 (10) 0 (0)
Impaired wound healing 2 (5) 2 (5) 0 (0) 0 (0)
Bacterial peritonitis 1 (3) 1 (3) 0 (0) 0 (0)
Abdominal pain 1 (3) 0 (0) 0 (0) 0 (0)
Gastroenteritis 1 (3) 0 (0) 0 (0) 0 (0)
Renal colic 1 (3) 0 (0) 0 (0) 0 (0)
Infections and infestations
Any event 17 (45) 7 (18) 4 (40) 3 (30)
MD, multiple dose; SAD, single ascending dose; UC, ulcerative colitis.
1126 Rutgeerts PJ, et al. Gut 2013;62:1122–1130. doi:10.1136/gutjnl-2011-301769
Inflammatory bowel disease
dose-dependent trend in the duration of occupancy in the
actively treated patients. For the cohorts receiving single intra-
venous doses of 0.3, 1.0 and 10 mg/kg, cohort mean occupancy
was maintained for approximately 2 weeks, 6 weeks and
10 weeks, respectively. The extent and duration of β7 occupancy
was similar in the 3 mg/kg SC and 3 mg/kg intravenous cohorts,
with cohort mean occupancy maintained for approximately
10 weeks.
For the cohorts administered multiple SC doses of 0.5 mg/kg
and 1.5 mg/kg etrolizumab, cohort mean occupancy was main-
tained for ∼2–4 weeks postfinal dose (day 57), whereas in the
cohorts dosed with 3 mg/kg SC and 4 mg/kg intravenous, there
was an extended duration of occupancy which was maintained
for ∼8–12 weeks postfinal dose. The duration of occupancy was
also longer when comparing the cohort receiving a single SC
dose of 3 mg/kg etrolizumab (∼10 weeks) compared with those
receiving multiple SC doses of 3 mg/kg (∼12 weeks).
Recovery of unoccupied β7 receptors on gut-homing T lympho-
cytes was associated with decreasing serum drug concentrations. A
consistent PK–PD relationship was observed in both the single
dose and MD cohorts in which a minimum serum concentration
range of 0.05–2.7 μg/ml of etrolizumab (mean ± SD =0.5
±0.6 μg/ml, median =0.3 μg/ml) maintained occupancy of CD4+
CD45RA-β7high T lymphocytes (see supplemental figure 1).
There was no change from baseline in the total lymphocyte
count in patients who received etrolizumab (data not shown).
Clinical activity
In the SAD stage, individual changes in MCS show a trend for a
decrease in the MCS in the low dose etrolizumab treated groups,
especially in those where etrolizumab was administered SC
(figure 4). In the MD stage, there was a similar trend for decrease
in MCS in the low dose SC groups treated with etrolizumab
(figure 4). The trend for decrease in the MCS in the etrolizumab
treated groups was not different from that observed in the placebo
treated patients and is confounded by the imbalanced use of oral
corticosteroids in the placebo treated patients compared with the
etrolizumab treated groups (table 1). Endoscopy scores were evalu-
ated as an exploratory end point and tracked well with the overall
MCS (supplementary figure 2).
DISCUSSION
The humanised monoclonal antibody etrolizumab targets the β7
subunit of the α4β7 and αEβ7 integrin heterodimer receptors.
In this phase I study, etrolizumab was safe and well tolerated in
patients with moderate to severely active UC. PK data indicate
that etrolizumab has acceptable PK parameters to enable
monthly SC administration. There were no early indications that
etrolizumab is immunogenic on repeated intravenous or SC
administration. Etrolizumab achieves immediate occupancy of
β7 integrin expressed on peripheral blood T cells, the duration
of which is dose-dependent. Although the numbers are small,
and there is an imbalance in UC concomitant medication
between placebo and the active treatment arms in the MD stage
of the study, there is an early indication of clinical activity of
etrolizumab in patients with severe UC.
Clinical studies have demonstrated efficacy with an anti-α4
integrin antibody (natalizumab) for the treatment of CD.4 Unlike
natalizumab, which blocks the function of both α4β1 and α4β7
heterodimers, etrolizumab does not interfere with the function
of α4β1, an integrin heterodimer critical for the homing of leuco-
cytes to the central nervous system through interactions with
VCAM-1.41 Notably, treatment with natalizumab has been asso-
ciated with confirmed cases of PML.42 The selectivity of etrolizu-
mab was confirmed by its inability to inhibit adhesion of
α4β1+α4β7− Ramos cells to VCAM-1 at concentrations as high
as 100 nM (data not shown). Consistent with these in vitro data,
preclinical rodent studies have demonstrated that blockade ofβ7
integrin can prevent the recruitment of T cells to the inflamed
colon in a mouse model of IBD while having no effect on
Figure 2 Concentration–time profiles
following single or multiple doses
given by IV or SC administration. The
lower limit of quantification is
0.0125 μg/ml. IV, intravenous; MD,
multiple dose; SAD, single ascending
dose; SC, subcutaneous; LLOQ, lower
limit of quantitation.
Figure 3 Occupancy (mean ± SD) of β7 integrin on CD4
+CD45RA-β7high T lymphocytes following administration of etrolizumab
or placebo. BL, baseline; IV, intravenous; MD, multiple dose; SAD,
single ascending dose; SC, subcutaneous.
Rutgeerts PJ, et al. Gut 2013;62:1122–1130. doi:10.1136/gutjnl-2011-301769 1127
Inflammatory bowel disease
lymphocyte homing to the brain in a mouse model of multiple
sclerosis.31 34 43 In addition, healthy cynomolgus monkeys
treated with etrolizumab had an increase in peripheral blood
mucosal-homing CD45RA-β7high CD4+ T cells with no substan-
tial effect on CD4+ T cell subsets that home preferentially into
non-mucosal sites.31 Following 26 weeks of treatment, etrolizu-
mab induced a dose-dependent reversible decrease in
gut-associated lymphoid tissue in cynomolgus monkeys and lym-
phocytes in murine intestinal lamina propria.32 These findings
point to the ability of etrolizumab to specifically inhibit traffick-
ing of mucosal-associated leucocytes implicated in disease patho-
genesis of IBD while sparing the function of T cell subsets
expressing other integrins subunits, such as α4β1, which are crit-
ical for normal host protective immune responses.
Clinical efficacy has also been demonstrated with the
anti-α4β7 antibody vedolizumab (MLN-0002, LDP-02) in UC
and CD.35 36 As with vedolizumab, etrolizumab binds α4β7 but
is unique in that it also blocks binding of αEβ7 to its ligand
E-cadherin. Thus, etrolizumab could affect leucocyte compos-
ition within the gut mucosa through multiple mechanisms. First,
as discussed above, it could block α4β7-expressing leucocytes
from entering the gut by inhibiting their extravasation through
MAdCAM-1-expressing mucosal endothelial venules. Notably,
MAdCAM-1 expression is increased in patients with UC and
CD,13 and antibodies against β7 or α4β7 are effective in blocking
migration of lymphocytes into the inflamed gut mucosa in animal
models.31 33 34 43 Second, by inhibiting αEβ7 interactions with
E-cadherin, it could directly affect retention of leucocytes within
Figure 4 Individual patient changes
in Mayo Clinic score. IV, intravenous;
MD, multiple dose; SAD, single
ascending dose; SC, subcutaneous;
TNF, tumour necrosis factor.
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the intestinal mucosa.17 αE integrin expression is very low in per-
ipheral blood and is found primarily on gut resident cells, includ-
ing intraepithelial lymphocytes44 and dendritic cells.45 More
than 90% of intraepithelial lymphocytes and 50% of T cells in
the human intestinal lamina propria express αEβ7 integrin, sug-
gesting a distinctive role in mucosal immunology.46 47 In add-
ition, αEβ7 is expressed on intestinal dendritic cells, which have
been implicated in the generation of gut-tropic effector T cells.48
Importantly, intraepithelial lymphocytes may exhibit cytotoxic
activity against epithelial cells19 20 and cells expressing αEβ7
integrin are pathogenic in mouse models of colitis and acute graft
versus host disease.23 49 Thus, etrolizumab represents a novel
therapeutic approach for UC by virtue of its unique ability to
inhibit both recruitment and retention of potentially pathogenic
immune cells in the inflamed gut mucosa.
α4β7 And αEβ7 can regulate trafficking and retention of
immune cells in both the intestine and other mucosal tissues
such as the lung. Blockade of these integrins could theoretically
impact immune function at these sites, potentially leading to
opportunistic infection. Intraepithelial lymphocytes expressing
αEβ7 play an important role in intestinal immunity to
Toxoplasma gondii.50 However, αEβ7 has recently been
reported to be dispensable for immunity to the intestinal hel-
minth pathogen Trichuris muris.51 Thus, αEβ7 and intraepithe-
lial lymphocytes participate in mucosal immune responses but
their relative importance is unclear and would likely need to be
evaluated on a pathogen-by-pathogen basis. We have not directly
evaluated the effect of β7 integrin blockade in animal models of
opportunistic or enteric infection, but in our 26-week toxicol-
ogy studies in mice and cynomolgus monkeys, there were no
instances of enteric infection despite an etrolizumab-induced
decrease in gut-associated lymphoid tissue.32 Similarly, there
were no pulmonary safety signals in our study. In addition, our
observation of no change from baseline in the total blood
lymphocyte count in patients who received etrolizumab reflects
the relatively small percentage of leucocytes affected by binding
of etrolizumab.
The favourable safety profile observed with etrolizumab treat-
ment in this trial warrants larger and longer-term studies to
confirm our findings with etrolizumab in moderate to severe
UC. A definitive phase II study is currently underway.
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